Licensing · MENA · Announced 15 Sept 2026
Shilpa Biologicals → SPIMACO
Licensing deal between Shilpa Biologicals (India) and SPIMACO (Saudi Arabia), covering Nivolumab biosimilar, announced 15 Sept 2026. Value: Undisclosed.
Parties: Shilpa Biologicals Pvt. Ltd (India) → SPIMACO (Saudi Arabia)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- MENA; Saudi Arabia manufacturing base
- Therapeutic area
- Oncology
- Assets
- Nivolumab biosimilar; Pembrolizumab biosimilar
- Announced
- 15 Sept 2026
Our analysis
SPIMACO Bio takes exclusive MENA rights to Shilpa's anti-PD-1 biosimilars — its nivolumab program (codes SBM-05/SBM-06) and a pembrolizumab biosimilar — with a phased technology transfer to localize manufacturing in Saudi Arabia. Shilpa develops, supplies and keeps the IP; SPIMACO Bio leads SFDA/MENA registration, market access, commercialization and distribution, and receives the transferred capability over time.
The assets — precise, and their real stage.
The full analysis is free to read with a work email on this page.
Source: Spimaco newsletter